Mohit Manrao, SVP, Head of US Oncology at AstraZeneca, shared a post on LinkedIn:
“This post is intended for a US audience.
I’m proud to share that the FDA has approved AstraZeneca’s MATTERHORN regimen for treatment of adult patients with resectable, early stage and locally advanced gastric and gastroesophageal junction (GEJ) cancers. This marks a significant milestone in a setting that has seen limited innovation in treatment options for over two decades!
We’re committed to pushing the boundaries of science, so that people with rare and tough-to-treat cancers have more treatment options available and better outcomes.
Gastric and GEJ cancers are often diagnosed at advanced stages once they are more challenging to treat. Despite standard surgery and chemotherapy, approximately one in four people with gastric cancer still develop recurrent disease within one year. The approval of the MATTERHORN regimen represents a major step forward in improving outcomes and offering renewed hope to those affected by this devastating disease.
Read more about the approval news.”
You can also read: MATTERHORN Trial at ESMO 2025: Durvalumab Plus FLOT in Resectable Gastric and GEJ Adenocarcinoma
